Fig. 2From: Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized triala Comparison of 5-year DFS rate between AML and ALL; b 5-year OS rate between AML and ALLBack to article page